RECENT NEWS

Bio-Rad Laboratories has expanded its precision oncology research portfolio with new tools designed to support mutation detection research, liquid biopsy workflows, tumor-informed assay development, molecular residual disease (MRD) research, and multiplex biomarker analysis.

A new scientific study by researchers at Karolinska Institutet, Danderyd Hospital and Uppsala University demonstrates that samples collected using a non-invasive method called PExA can be used to measure virus-specific antibodies from the small airways.

Scientists have carried out one of the largest experimental studies of breast cancer variants to date, helping pinpoint genetic changes that are most likely to contribute to the development of the disease.

Agilent Technologies has announced the launch of the NovoStation Sample Preparation System, a new automated platform designed to help laboratories simplify and streamline flow cytometry sample preparation.

A world-leading new trial is being launched across at least 200 GP practices in England aimed at providing earlier diagnosis for a range of the most common cancers.

Researchers at the University of California, Riverside (UCR) have identified a new strategy for treating systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system attacks healthy tissues.

The UK Government has confirmed eligibility for the spring 2027 COVID-19 vaccination programme in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI).

The UK Health Security Agency (UKHSA) is conducting a human biomonitoring study as part of a programme of work to improve understanding of levels of per- and polyfluoroalkyl substances (PFAS) and other chemicals such as lead, arsenic and flame retardants, in the UK population and the potential implications for health.

The Royal College of Pathologists (RCPath) has joined calls from Which? for consumers to carefully consider the accuracy and suitability of rapid vitamin D self-test kits that are sold on the high street.

OGT has announced the launch of four newly available IVDR-certified CytoCell fluorescence in situ hybridisation (FISH) probes as part of its ongoing commitment to transition the CytoCell FISH portfolio from CE marking under the IVD Directive (IVDD) to the IVD Regulation (IVDR).

QuidelOrtho has launched the VITROS 450 chemistry system, a next-generation analyser designed to empower low-volume and community‑based laboratories with high-quality, reliable results.

Octopath AI, a UCL spinout developing artificial intelligence for digital pathology, has launched with £1.5 million in combined seed investment and grant funding, led by TwinPath Ventures.

APIS Assay Technologies and BIOTYPE have announced a commercial partnership to bring two molecular testing solutions to market under BIOTYPE’s ExaccType brand: the ExaccType ESR1 dPCR Kit and the ExaccType DPYD Kit.

Roche has announced the global launch of the VENTANA BAP1 (SP527) test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC).

New research by the Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with the GSK Vaccines Institute for Global Health, has moved a vaccine against the highly contagious group A Streptococcus bacterium (Strep A) a step closer to reality.

A £4 million UK research collaboration is set to accelerate the development of affordable, adaptable RNA vaccines to protect animal health, strengthen food security and enhance the UK's preparedness for future disease outbreaks.

The Royal Marsden has opened a pioneering cancer genomics centre in Sutton, designed to help more patients across the UK benefit from personalised cancer treatments and clinical trials.

US-based Real Diagnostics, a clinical laboratory specialising in high-complexity molecular infectious disease and toxicology testing, has announced the acquisition of SimplyTest, a leading provider of saliva-based diagnostic tests for oral health.

Abbott has announced the commercial availability of its next-generation Oncodetect molecular residual disease (MRD) test, a personalised, tumour-informed, whole-genome sequencing test designed to provide molecular insights during and after cancer treatment.

Using the online Dynamic Purchasing System (DPS), NHS Trusts across England and Wales can now source and bring into clinical use the iFAST ONE ultra-rapid AST technology direct from iFAST Diagnostics.